Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the stock in a transaction dated Wednesday, July 22nd. The shares were sold at an average price of $21.25, for a total transaction of $6,906,250.00. Following the completion of the sale, the insider directly owned 574,047 shares in the company, valued at approximately $12,198,498.75. The trade was a 36.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Surrozen Price Performance
SRZN stock opened at $19.40 on Wednesday. The company's 50 day simple moving average is $23.60 and its 200-day simple moving average is $25.28. Surrozen, Inc. has a 12 month low of $8.70 and a 12 month high of $35.00. The firm has a market capitalization of $225.23 million, a PE ratio of -0.52 and a beta of 0.51.
Surrozen (NASDAQ:SRZN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($11.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($10.56). The company had revenue of $5.00 million during the quarter, compared to analysts' expectations of $4.00 million. As a group, sell-side analysts anticipate that Surrozen, Inc. will post -7.2 earnings per share for the current year.
Institutional Trading of Surrozen
Several hedge funds and other institutional investors have recently bought and sold shares of SRZN. China Universal Asset Management Co. Ltd. grew its position in shares of Surrozen by 50.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company's stock valued at $34,000 after purchasing an additional 500 shares during the period. Citadel Advisors LLC increased its stake in Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company's stock valued at $179,000 after purchasing an additional 3,424 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in Surrozen during the fourth quarter worth about $99,000. Schonfeld Strategic Advisors LLC lifted its position in Surrozen by 8.1% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 74,645 shares of the company's stock worth $1,687,000 after buying an additional 5,621 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company's stock worth $277,000 after buying an additional 5,702 shares during the last quarter. 66.57% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
SRZN has been the subject of a number of analyst reports. TD Cowen started coverage on Surrozen in a report on Tuesday, April 21st. They issued a "buy" rating for the company. HC Wainwright reaffirmed a "buy" rating and set a $44.00 price objective (up from $36.00) on shares of Surrozen in a research note on Thursday, May 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Surrozen in a research report on Friday, July 17th. Finally, Zacks Research downgraded shares of Surrozen from a "hold" rating to a "strong sell" rating in a research note on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $42.00.
Read Our Latest Research Report on Surrozen
About Surrozen
(
Get Free Report)
Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.
The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
